Congress quietly shields biotech drug makers from Medicare price negotiation
S. 1930 — Small Biotech Innovation Act · Filed by Bill Cassidy (R-LA) · 1 cosponsor · Introduced Jun 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill exempts drugs made by small biotech companies from Medicare's drug price negotiation program, starting in 2029. A small biotech company with 5 or fewer drugs can avoid price negotiation if it spends at least 30–70% of revenue (depending on how many drugs it makes) on research and development. The exemption disappears if the company is acquired by a larger manufacturer.
Why we flagged it
The bill's core function is to shield small biotech manufacturers from Medicare price negotiation, creating a regulatory exemption that protects drug pricing power. It is framed as innovation support but operates as a narrow industry benefit.
What the text implies
- The 'applicable percent' R&D spending threshold (30–70%) is self-reported and verified only through annual application; there is no independent audit mechanism, creating potential for gaming or misclassification.
- The exemption applies indefinitely once a drug qualifies, even if R&D spending drops below the threshold in future years, locking in price protection.
The full analysis lists 4 implications of this text.
Who stands to gain
small biotech manufacturers; pharmaceutical companies with 5 or fewer single-source drugs; drug manufacturers with high R&D spending ratios